Back to: Research : Research Results

Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)

Primary and Ancillary Study Results

The Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) was a large, randomized, placebo-controlled trial conducted at several sites across the United States. The GAIT team, funded by NCCAM and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, actually conducted two studies:

Primary GAIT Study Results: February 2006

Researchers led by rheumatologist Daniel O. Clegg, M.D., of the University of Utah School of Medicine, conducted the 4-year primary GAIT study at 16 sites. The results, published in the New England Journal of Medicine, February 22, 2006, showed that the popular dietary supplement combination of glucosamine plus chondroitin sulfate did not provide significant relief from osteoarthritis pain among all participants. However, a smaller subgroup of study participants with moderate-to-severe pain showed significant relief with the combined supplements.

Ancillary GAIT Study Results: October 2008

GAIT researchers led by rheumatologists Allen D. Sawitzke, M.D., and Daniel O. Clegg, M.D., both of the University of Utah School of Medicine, conducted a 2-year ancillary GAIT study at nine sites with a subset of participants from the original GAIT study. The ancillary study results, published in Arthritis & Rheumatism, October 2008, showed that glucosamine and chondroitin sulfate, together or alone, appeared to fare no better than placebo in slowing loss of cartilage in knee osteoarthritis. However, interpreting the study results is complicated because participants taking placebo had a smaller loss of cartilage, or joint space width, than predicted.

Related Resources